A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis.

An American kindred was found to have hereditary amyloidosis with cutaneous and cardiac involvement. Characterization of fibrils isolated from skin identified the amyloid protein as the N-terminal 90 to 100 residues of apolipoprotein A-1. Sequence of the apolipoprotein A-1 gene was normal except for a G/C transversion at position 1638 which predicts an Arg to Pro substitution at residue 173. This mutation, unlike previously described amyloidogenic mutations is not in the N-terminal fragment which is incorporated into the fibril. The mutation is at the same residue as in apolipoprotein A-1 Milano (Arg173Cys) which does not result in amyloid formation. Decreased plasma HDL cholesterol levels in carriers of the Arg173Pro mutation suggest an increased rate of catabolism as has been shown for the amyloidogenic Gly26Arg mutation. This suggests that altered metabolism caused by the mutation may be a significant factor in apolipoprotein A-1 fibrillogenesis.

[1]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[2]  R. Gregg,et al.  A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. , 1990, Genomics.

[3]  D. Booth,et al.  Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. , 1998, Kidney international.

[4]  R. Mahley,et al.  Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I. , 1983, The Journal of biological chemistry.

[5]  D. Booth,et al.  Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. , 1996, The Journal of clinical investigation.

[6]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[7]  D. Booth,et al.  A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis. , 1995, QJM : monthly journal of the Association of Physicians.

[8]  H. Schägger,et al.  Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. , 1987, Analytical biochemistry.

[9]  J. Soria,et al.  Molecular basis for fibrinogen Dusart (A alpha 554 Arg-->Cys) and its association with abnormal fibrin polymerization and thrombophilia. , 1993, The Journal of clinical investigation.

[10]  J. Liepnieks,et al.  Variant apolipoprotein AI as a major constituent of a human hereditary amyloid. , 1988, Biochemical and biophysical research communications.

[11]  D. Rader,et al.  In vivo metabolism of a mutant apolipoprotein, apoA-IIowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. , 1992, Journal of lipid research.

[12]  J. Liepnieks,et al.  Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1. , 1999, The American journal of pathology.

[13]  R. Mahley,et al.  A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. , 1980, The Journal of clinical investigation.

[14]  M. Pras,et al.  The characterization of soluble amyloid prepared in water. , 1968, The Journal of clinical investigation.

[15]  J. Liepnieks,et al.  Hereditary renal amyloidosis associated with a mutant fibrinogen α–chain , 1993, Nature Genetics.

[16]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[17]  G. Franceschini,et al.  In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia. , 1993, The Journal of clinical investigation.